Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 74

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 74
---
. While these trace elements are critical for various physiological functions, imbalances—whether due to excess or deficiency —can drive oxidative stress and enzymatic activities, leading to cellular damage, telomere shortening, and accelerated aging. This oxidative burden is also linked to age-related conditions and certain cancers. In October 2025, Telomir-1 displayed the potential to decrease the viability of aggressive triple-negative breast cancer (TNBC) cells - a highly invasive form of breast cancer that lacks hormone and HER2 receptors, offers limited treatment options, and carries one of the poorest survival rates among breast cancer subtypes.

Telomir-1 is currently undergoing preclinical investigation, with the goal of submitting an Investigational New Drug (IND) application to the FDA. If accepted, this submission would enable progression to human clinical trials. Our research focuses on Telomir-1’s potential to interrupt, regulate, and prevent inflammatory pathways and enzymatic intracellular processes responsible for cellular metal imbalances. Preliminary studies suggest that Telomir-1 may achieve these outcomes by selectively binding to and exchanging between metal ions in a form- and dose-dependent manner, slowing enzyme reactivity, and preserving cellular functions. If clinical trials demonstrate its efficacy and it gains FDA and other regulatory approvals, we believe Telomir-1 could serve as a non-toxic, orally administered ion-overload regulator with the potential to balance enzyme and pathway overactivity caused by excessive metal reactivity.

To
date, we have completed multiple preclinical studies on Telomir-1, including those demonstrating that Telomir-1 is non-mutagenic and
possesses strong biological and metal-binding properties (Graphic 1). Using various methodologies, including chemical and biological
activity, as well as toxicity studies, we continue to uncover evidence supporting Telomir-1’s potential to address metal-overload
conditions. Additionally, recent studies have confirmed that Telomir-1 exhibits strong binding affinities for copper and iron, with reduced
binding affinity for zinc and is capable to reduce intracellular iron from living cells.

| 42 |

<div align='center'>Graphic 1: Telomir-1 is capable binding to several metal ions</div>

We collaborate with third-party organizations to conduct research and advance development efforts. One such partner, We work with Recipharm and Smart Assays to assess Telomir-1’s binding properties and investigate ion competition and exchange under varying conditions, further refining its therapeutic potential.

An example of these findings is illustrated